IP Library Patent Application 12872566
Patent Application
App. No. 12/872,566

Stable Aerosol Topical Foams Comprising a Hypochlorite Salt

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
12/872,566
Abstract

Described herein are compositions useful in the treatment of atopic dermatitis and other skin conditions, which compositions exhibit enhanced stability. The compositions contain a hypochlorite salt, useful for its antimicrobial properties, and are non-irritating when applied to the skin. The compositions also provide enhanced moisturizing properties. The compositions can be formulated into a topical aerosol foam with inert, non-flammable propellants, such as hydrofluoroalkanes, and may be used in cosmetics or pharmaceuticals.

Claims (36)

1 . A composition, comprising a concentrate and a propellant, wherein

the concentrate comprises

an amount of a hypochlorite salt, wherein the amount of the hypochlorite salt is about 0.0001% to about 1.5% by weight of the concentrate;

an amount of a humectant, wherein the amount of the humectant is about 15% to about 35% by weight of the concentrate;

an amount of water, wherein the amount of water is about 60% to about 80% by weight of the concentrate; and

an amount of a stabilizer, wherein the amount of the stabilizer is about 0.5% to about 5.0% by weight of the concentrate; and

the propellant is a hydrofluoroalkane propellant.

2 . The composition of claim 1 , wherein the composition is in an aerosol container.

3 . The composition of claim 2 , wherein when the aerosol container is actuated, the composition is expelled as a foam.

4 . A method of treating a condition of a subject in need thereof, comprising

applying to an affected area of the subject an effective amount of a foam prepared from a composition of claim 1 .

5 . The method of claim 4 , further comprising

expelling from an aerosol container a composition of claim 1 , thereby preparing a foam.

6 . The method of claim 4 or 5 , wherein the subject is human.

7 . The method of claim 6 , wherein the affected area of the subject is selected from the group consisting of the face, earlobes, neck, scalp, genitals, eyelids, palms, fingers, feet, exural surfaces of joints, extensor aspects of joints, and any combination thereof

8 . The method of claim 6 , wherein the affected area of the subject is the face.

9 . The method of claim 4 or 5 , wherein the condition is selected from the group consisting of atopic dermatitis, contact dermatitis, xerotic eczema, seborrhoeic dermatitis, psoriasis, dyshidrosis, discoid eczema, venous eczema, dermatitis herpetiformis, neurodermatitis, autoeczematization, herpes simplex I, other topical herpes or viral infections, common cold sores and fever blisters, ringworm, impetigo, and other viral, fungal, or bacterial infections of the skin.

10 . The method of claim 9 , wherein the condition is atopic dermatitis.

11 . The method of claim 9 , wherein the subject is human.

12 . The method of claim 4 or 5 , wherein the composition is applied once daily or twice daily.

13 . A composition, comprising a concentrate and a propellant, wherein

the concentrate comprises

an amount of a hypochlorite salt, wherein the amount of the hypochlorite salt is about 0.0001% to about 1.5% by weight of the concentrate;

an amount of a viscosity modifier, wherein the amount of the viscosity modifier is about 0.1% to about 6% by weight of the concentrate;

an amount of a surfactant, wherein the amount of the surfactant is about 0.01% to about 1% by weight of the concentrate;

an amount of water, wherein the amount of water is about 80% to about 99% by weight of the concentrate; and

an amount of a stabilizer, wherein the amount of the stabilizer is about 0.01% to about 1.0% by weight of the concentrate; and

the propellant is a hydrofluoroalkane propellant.

14 . The composition of claim 13 , wherein the composition is in an aerosol container.

15 . The composition of claim 14 , wherein when the aerosol container is actuated, the composition is expelled as a foam.

16 . A method of treating a condition of a subject in need thereof, comprising

applying to an affected area of the subject an effective amount of a foam prepared from a composition of claim 13 .

17 . The method of claim 16 , wherein the affected area of the subject is selected from the group consisting of the face, earlobes, neck, scalp, genitals, eyelids, palms, fingers, feet, exural surfaces of joints, extensor aspects of joints, and any combination thereof.

18 . The method of claim 16 , wherein the condition is selected from the group consisting of atopic dermatitis, contact dermatitis, xerotic eczema, seborrhoeic dermatitis, psoriasis, dyshidrosis, discoid eczema, venous eczema, dermatitis herpetiformis, neurodermatitis, autoeczematization, herpes simplex I, other topical herpes or viral infections, common cold sores and fever blisters, ringworm, impetigo, and other viral, fungal, or bacterial infections of the skin.

19 . The method of claim 18 , wherein the subject is human.

20 . The method of claim 16 , wherein the composition is applied once daily or twice daily.

Assignments (4)
RELEASE OF SECURITY INTEREST Recorded Sep 27, 2013
From: MIDCAP FUNDING III, LLC
To: PRECISION DERMATOLOGY COMPANY, INC.; ONSET DERMATOLOGICS, LLC; PROSKIN, LLC; PRECISION MD, LLC; TP CREAM SUB, LLC; TP LOTION SUB, LLC
Reel/Frame 031296/0492 →
SECURITY AGREEMENT Recorded May 18, 2012
From: PRECISION DERMATOLOGY, INC.; ONSET DERMATOLOGICS, LLC; PROSKIN LLC; PRECISION MD LLC; TP CREAM SUB, LLC; TP LOTION SUB, LLC
To: MIDCAP FUNDING III, LLC
Reel/Frame 028234/0424 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 25, 2011
From: COLLEGIUM PHARMACEUTICAL, INC.
To: PRECISION DERMATOLOGY, INC.
Reel/Frame 025690/0908 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 27, 2010
From: ABEL, DOUGLAS; GURGE, RONALD M.; TRUMBORE, MARK W.
To: COLLEGIUM PHARMACEUTICAL, INC.
Reel/Frame 025202/0636 →